Literature DB >> 12473968

Citalopram for the treatment of adolescent anxiety disorders: a pilot study.

Jefferson B Prince1, Jeff Q Bostic, Michael Monuteaux, Kenneth Brown, Suzanne Place.   

Abstract

Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed. Patients were retrospectively assessed using the Clinical Global Impression (CGI)-Severity scale at the beginning and end of treatment. Eighty-two percent (14/17) of patients were rated as much or very much improved on the CGI-Improvement scale after treatment with citalopram. Patients were treated for an average of 156-/+85.1 days at a mean dose of 32.3-/+18.5 mg/day of citalopram. Fifty-three percent (9/17) of this sample had previous exposure to alternative selective serotonin reuptake inhibitors, and 89% (8/9) of those patients responded positively to citalopram. Citalopram appeared well tolerated, with only one patient discontinuing treatment due to side effects. In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473968

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  2 in total

1.  Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.

Authors:  Tao Jiang; Zhengxing Rong; Yiping Xu; Bing Chen; Yifan Xie; Congying Chen; Yang Lu; Yifeng Shen; Huafang Li; Jing Sun; Hongzhuan Chen
Journal:  Clin Drug Investig       Date:  2013-01       Impact factor: 2.859

2.  Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.

Authors:  Stacey L Aldrich; Ethan A Poweleit; Cynthia A Prows; Lisa J Martin; Jeffrey R Strawn; Laura B Ramsey
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.